After skepticism and tight vote at adcomm, FDA approves ChemoCentryx's rare disease drug

Nicole DeFeudis

Editor

After a tight advisory committee vote back in May that tilted just slightly in favor of approving ChemoCentryx’s avacopan, the FDA has officially cleared …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After skepticism and tight vote at adcomm, FDA approves ChemoCentryx's rare disease drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Af­ter skep­ti­cism and tight vote at ad­comm, FDA ap­proves Chemo­Cen­tryx's rare dis­ease drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

After skepticism and tight vote at adcomm, FDA approves ChemoCentryx's rare disease drug

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry